| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|
| Net change in cash and cash equivalents | 37,602,558 | -843,007 | -1,144,396 |
| Cash and cash equivalents at beginning of period | 1,174,608 | - | - |
| Cash and cash equivalents at end of period | 38,777,166 | - | - |
Qualigen Therapeutics, Inc. (QLGN)
Qualigen Therapeutics, Inc. (QLGN)